Synergistic interaction between a mixed ligand copper (II) chelate complex and two anticancer agents in T47D human breast cancer cells in vitro

Journal of B.U.ON.

Volumn 11, Issue 4, 2006, Pages 469-476

  Geromichalos, George D ^a   Trafalis, D T ^b   Katsoulos, G A ^c   Papageorgiou, A ^a   Dalezis, P ^a   Triandafillidis, E B ^a   Hadjikostas, C C ^c   Athanassiou, A ^b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

5 fluorouracil; Ascorbic acid; Bleomycin; Copper complexes; Cytotoxicity; Molecular modelling; Synergy

Indexed keywords

ASCORBIC ACID; BLEOMYCIN; COPPER COMPLEX; COPPER SALICYLATE; FLUOROURACIL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; COPPER SALICYLATE COMPLEX; LIGAND; ORGANOMETALLIC COMPOUND; SALICYLIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CYTOTOXICITY; DNA BINDING; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; RNA BINDING; STRUCTURE ACTIVITY RELATION; BREAST TUMOR; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECT; DRUG INTERACTION; METABOLISM;

ANTINEOPLASTIC AGENTS; BLEOMYCIN; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG INTERACTIONS; DRUG SYNERGISM; FLUOROURACIL; HUMANS; LIGANDS; ORGANOMETALLIC COMPOUNDS; SALICYLATES; TUMOR CELLS, CULTURED;

EID: 33947543637     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Farrell N (ed). Transition Metal Complexes as Drugs and Chemotherapeutic Agents. Dordrecht: Kluwer Academic, 1989, Vol 11.
2. Pickart L, Goodwin WH, Burgua W, Murphy TB, Johnson DK. Inhibition of the growth of cultured cells and an implanted fibrosarcoma by aroylhydrazone analogs of the Gly-His-Lys-Cu(II) complex. Biochem Pharmacol 1983; 32: 3868-3871.
3. Carter DC, He XM. Structure of human serum albumin. Science 1990; 249: 302-303.
4. Waring MJ. DNA modification and cancer. Ann Rev Biochem 1981; 50: 159-192.
5. Raptopoulou CP, Paschalidou S, Pantazaki AA et al. Bis (Acetato)Bis(1-Methyl-4,5-Diphenylimidazole) Copper(II): Preparation, Characterization, Crystal Structure, DNA Strand Breakage and Cytogenetic Effect. J Inorg Biochem 1998; 71: 15-27.
6. Sartorelli AC, Agrawal KC, Tsiftsoglou AS, Moore EC. Characterization of the biochemical mechanism of action of a-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Adv Enzyme Regul 1977; 15: 117-139.
7. Scovill JP, Klayman DL, Lambrose C, Childs GF, Antholine W, Petering DH. 2-acetylpyridine thiosemicarbazones. Derivatives of 2-acetylpyridine 1-oxide as potential antimalarial agents. J Med Chem 1984; 27: 87-91.
8. Sorenson JRJ. Copper complexes offer a physiological approach to treatment of chronic diseases. Prog Med Chem 1989; 26: 437-568.
9. Sorenson JRJ, Soderberg LSF, Chang LW et al. Copper, iron, manganese, and zinc 3,5-diisopropylasalicylate complexes increase survival of gamma irradiated mice. Eur J Med Chem 1993; 28: 221-229.
10. Baquial JGL, Sorenson JRJ. Down-regulation of NADPH diaphorase (nitric oxide synthase) may account for the pharmacological activities of Cu(II)2(3,5-diisopropylasalicylate)4. J Inorg Biochem 1995; 60: 133-148.
11. Greenaway FT, Norris LJ, Sorenson JRJ. Mononuclear and binuclear copper (II) complexes of 3,5-3,5-diisopropylsalicylic acid. Inorg Chim Acta 1988; 145: 279-284.
12. Greenaway FT, Hahn JJ, Xi N, Sorenson JRJ. Interaction of Cu(II) 3,5-diidopropylsalicylate with human serum albuminan evaluation of spectroscopic data. Biometals 1998; 11: 21-26.
13. Konstandinidou M, Kourounaki A, Hadjipetrou L et al. Antiinflammatory Properties of Complexes of Diclofenac with Transition Metals. J Inorg Biochem 1998; 70: 63-69.
14. Geromichalos GD, Kortsaris AH, Hadjikostas CC, Katsoulos GA, Kyriakidis DA. The growth inhibitory effect of some mixed-ligand copper(II) complexes on normal and human breast cancer cell lines. 10th Balkan Biochem Biophys Days, Varna, Bulgaria. Abstracts book, 1994, p 263 (abstr).
15. Geromichalos GD, Kortsaris AH, Hadjikostas CC, Katsoulos GA, Kyriakidis DA. Evaluation of the cytotoxic action of some mixed-ligand copper(II) complexes on a variety of cultured human tumor cell lines using an XTT-based colorimetric assay. Proc 42nd Sci Conf Hellenic Biochem Biophys Soc. Biochem Biophys Newsletter, Athens, Greece, 1995, pp 100-101 (abstr).
16. Geromichalos GD, Katsoulos GA, Hadjikostas CC, Kortsaris AH, Kyriakidis DA. In vitro synergistic cytotoxic effects of epirubicin, mitomycin-C and a number of recently synthesized Cu(II) complexes on HeLa-S3 cervical cancer cell line. 2nd Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries. Abstracts book. Ioannina, Greece, 1995, p 50 (abstr).
17. Geromichalos GD, Katsoulos GA, Hadjikostas CC et al. Effects of cyclophosphamide, vincristine and two novel Cu(II) complexes on cell cycle of Raji cells in vitro. 2nd Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries. Abstracts book Ioannina, Greece, 1995, p 51 (abstr).
18. Geromichalos GD, Katsoulos GA, Hadjikostas CC et al. Study of the cytotoxic action of some novel copper(II) complexes on various cultures of normal and tumor cell lines. Analysis of DNA with flow cytometry. 8th Greek Oncology Congress, Oncological Archives, Athens, Greece, 1995, p 18 (abstr).
19. Geromichalos GD, Katsoulos GA, Hadjikostas CC et al. Antagonistic effects of Paclitaxel and a novel Cu(II) complex on T47D human breast cancer cells, 11th Balkan Biochem Biophys Days, Thessaloniki, Greece. 1997 Abstracts book, p 311 (abstr).
20. Kyriakidis DA, Kortsaris AH, Katsoulos GA et al. Antiproliferative activity of new Copper(II) complexes on different cancer cell lines. 4th FIGPS Meeting in Inorganic Chemistry, Corfu, Greece. Abstracts book 1997, No SLA 13 (abstr).
21. Kissa FK, Bolos Ch, Papazisis KT, Geromichalos GD, Kyriakidis DA, Kortsaris AH. Study on in vitro cytotoxic effect of a new series of Copper(II) complexes against various cancer and normal cell lines. 9th Hellenic Congress of Oncology, Athens, Greece. Abstracts book, 1997, No 5 (abstr).
22. Geromichalos GD, Katsoulos GA, Papazisis KT et al. Combined effects of a novel Copper (II) complex with a panel of anticancer drugs against a breast cancer cell line. Proc 49th Sci Conf Hellenic Biochem and Biophys Soc, Heraklion, Greece. Biochem Biophys Newsletter 1998, p 45 (abstr).
23. Geromichalos GD, Katsoulos GA, Hadjikostas CC, Kortsaris AH, Kyriakidis DA. In vitro synergistic effect of some novel Cu(II) complexes in combination with epirubicin and mitomycin C against HeLa-S3 cervical cancer cell line. Anti-Cancer Drugs 1996; 7: 469-473.
24. Geromichalos GD, Katsoulos GA, Hadjikostas CC, Kortsaris AH, Kyriakidis DA. In vitro combination effect of a new series of copper(II) complexes with cisplatin or epirubicin on human breast and cervical cancer cell lines. Drugs Exper Clin Res 1998; 24: 93-104.
25. Wang Y, Van Ness B. Site-specific cleavage of supercoiled DNA by ascorbate/Cu(II). Nucleic Acids Res 1989; 17: 6915-6926.
26. Geromichalos GD, Katsoulos GA, Papazisis KT, Hadjikostas CC, Kortsaris AH, Kyriakidis DA. Synergistic interaction between a recently synthesized copper (II) complex and bleomycin in human breast cancer cells in vitro. 1st International Conference on Chemical Sciences and Industry of the Chemical Societies of the South-East European Countries, Halkidiki, Greece. Abstracts book 1998, pp 1-4, No P044 (abstr).
27. Geromichalos GD, Katsoulos GA, Papazisis KT, Hadjikostas CC, Kortsaris AH, Kyriakidis DA. Synergistic cytotoxicity of carboplatin and a recently synthesized copper (II) complex in human breast cancer cells in vitro. 1st International Conference on Chemical Sciences and Industry of the Chemical Societies of the South-East European Countries, Halkidiki, Greece. Abstracts book 1998, pp 1-4, No P045 (abstr).
28. Heidelberger C, Chandhari NK, Dannenberg P et al. Fluorinated pyrimidines: A new class of tumor inhibitory compounds. Nature 1957; 170: 663-666.
29. Sommer A, Santi DV. Purification and amino acid analysis of an active site peptide from thymidilate synthetase containing covalently bound 5-fluoro-2-deoxyuridilate and methylene tetrachloride. Biochem Biophys Res Commun 1974; 57: 689-696.
30. Petering DH, Byrnes RW, Antholine WE. The role of redox-active metals in the mechanism of action of bleomycin. Chem Biol Interact 1990; 73: 133-141.
31. Ciriolo MR, Magriozzo RS, Peisach J. Microsom-stimulated activation of ferrous bleomycin in the presence of DNA. J Biol Chem 1987; 262: 6290-6295.
32. Geromichalos GD, Katsoulos GA, Trafalis DT, Hadjikostas CC, Papageorgiou A. Synergistic interaction between a novel mixed ligand copper(II) chelate complex and a panel of anticancer agents in T47D human breast cancer cells in vitro. J BUON 2005; 10: 235-240.
33. Geromichalos GD, Katsoulos GA, Papageorgiou A et al. Cytotoxic effects of a mixed ligand copper(II) chelate complex against a panel of human and murine cancer cells in vitro. Theoretical study of the mechanism of biologic action through molecular modeling. J BUON 2004; 9: 433-441.
34. Keydar I, Chen L, Karby S et al. Establishment and characterization of a cell line of a human breast carcinoma origin. Eur J Cancer 1979; 15: 659-663.
35. Gorman A, McCarthy J, Finucane D, Reville W, Cotter T. Morphological assessment of apoptosis. In: Cotter TG and Martin SJ (eds): Techniques in Apoptosis. A User's Guide. London: Portland Press Ltd, 1996, pp 6-7.
36. Paull KD, Shoemaker RH, Boyd MR. The synthesis of XTT: a new tetrazolium reagent that is bioreducible to a water-soluble formazan. J Heterocyclic Chem 1988; 25: 911-914.
37. Scudiero DA, Shoemaker RH, Paull KD. Evaluation of a soluble tetrazolium/ formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-4833.
38. Monks A, Scudiero D, Shehan P. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83: 757-766.
39. Roem NW, Rodgers GH, Hatfield SM, Glasebrook AI. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 1991; 142: 257-261.
40. Jost LM, Kirkwood JM, Whiteside TL. Improved short-and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 1992; 147: 153-165.
41. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs of enzyme inhibitors. Adv Enzyme Reg 1984; 22: 27-55.